These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20634675)

  • 21. Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment.
    Vassiliou V; Kalogeropoulou C; Christopoulos C; Solomou E; Leotsinides M; Kardamakis D
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):264-72. PubMed ID: 17084550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.
    Altundag K; Dizdar O; Ozsaran Z; Ozkok S; Saip P; Eralp Y; Komurcu S; Kuzhan O; Ozguroglu M; Karahoca M
    Onkologie; 2012; 35(5):254-8. PubMed ID: 22868504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.
    Pecherstorfer M
    Expert Opin Pharmacother; 2004 Nov; 5(11):2341-50. PubMed ID: 15500381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
    Jensen AB; Wynne C; Ramirez G; He W; Song Y; Berd Y; Wang H; Mehta A; Lombardi A
    Clin Breast Cancer; 2010 Dec; 10(6):452-8. PubMed ID: 21147688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for breast cancer and bone metastases.
    Pecherstorfer M
    Womens Health (Lond); 2009 Mar; 5(2):149-63. PubMed ID: 19245353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers.
    Fulfaro F; Leto G; Badalamenti G; Arcara C; Cicero G; Valerio MR; Di Fede G; Russo A; Vitale A; Rini GB; Casuccio A; Intrivici C; Gebbia N
    J Chemother; 2005 Oct; 17(5):555-9. PubMed ID: 16323446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
    Heidenreich A; Ohlmann CH
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
    Geng CJ; Liang Q; Zhong JH; Zhu M; Meng FY; Wu N; Liang R; Yuan BY
    BMJ Open; 2015 Jun; 5(6):e007258. PubMed ID: 26038356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical implications of bisphosphonate for bone metastases of prostate cancer].
    Kitagawa Y; Konaka H; Mizokami A; Namiki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():356-9. PubMed ID: 18161131
    [No Abstract]   [Full Text] [Related]  

  • 33. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
    Broom R; Du H; Clemons M; Eton D; Dranitsaris G; Simmons C; Ooi W; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):244-57. PubMed ID: 19364633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A; Cueva J; Ruiz-Borrego M; Ponce J; Pérez-Fidalgo JA
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid in lung cancer with bone metastases: a review.
    Isla D; Afonso R; Bosch-Barrera J; Martínez N
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):421-6. PubMed ID: 23560837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.
    Chao TC; Chen DR; Chao TY; Chen SC; Yeh DC; Wang HC; Huang WT; Rau KM; Chang KJ; Yang TL; Lee KD; Tai CJ; Tseng LM; Hou MF
    Anticancer Res; 2013 Dec; 33(12):5543-7. PubMed ID: 24324095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
    Heras P; Kritikos K; Hatzopoulos A; Georgopoulou AP
    Eur J Cancer Care (Engl); 2009 Nov; 18(6):653-6. PubMed ID: 19552728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
    Ringe JD; Body JJ
    Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.